What is the projected market valuation of the Brain Tumor Diagnostics Market by 2035?

The Brain Tumor Diagnostics Market is projected to reach approximately 5.264 USD Billion by 2035. Read More

What was the market valuation of the Brain Tumor Diagnostics Market in 2024?

In 2024, the market valuation of the Brain Tumor Diagnostics Market was 2.49 USD Billion. Read More

What is the expected CAGR for the Brain Tumor Diagnostics Market during the forecast period 2025 - 2035?

The expected CAGR for the Brain Tumor Diagnostics Market during the forecast period 2025 - 2035 is 7.04%. Read More

Which companies are considered key players in the Brain Tumor Diagnostics Market?

Key players in the Brain Tumor Diagnostics Market include Siemens Healthineers, GE Healthcare, and Philips Healthcare, among others. Read More

What are the main modalities contributing to the Brain Tumor Diagnostics Market?

The main modalities include Neuroimaging, Biopsy, Laboratory Tests, and Genetic Testing, with Neuroimaging valued at 1.99 USD Billion by 2035. Read More

How does the market for genetic testing in brain tumor diagnostics appear to be evolving?

The market for genetic testing is projected to grow from 0.25 USD Billion in 2024 to 0.5 USD Billion by 2035. Read More

What imaging techniques are primarily utilized in brain tumor diagnostics?

The primary imaging techniques include Magnetic Resonance Imaging (MRI), Computed Tomography (CT), and Positron Emission Tomography (PET), with MRI expected to reach 1.99 USD Billion by 2035. Read More

What sample types are commonly used in brain tumor diagnostics?

Common sample types include Tissue Biopsy, Blood, and Cerebrospinal Fluid (CSF), with Tissue Biopsy projected to reach 1.99 USD Billion by 2035. Read More

How does the market for biomarkers in brain tumor diagnostics appear to be developing?

The market for biomarkers, including IDH1 and ATRX, is expected to grow significantly, with IDH1 projected to reach 0.999 USD Billion by 2035. Read More

Brain Tumor Diagnostics Market

Q: What diagnostic purposes are driving the Brain Tumor Diagnostics Market?

Key diagnostic purposes include Pre-Operative Diagnosis, Post-Operative Monitoring, Treatment Selection, and Prognosis Prediction. Read More

ID: MRFR/LS/7588-HCR

128 Pages

Vikita Thakur

Last Updated: April 06, 2026

Brain Tumor Diagnostics Market Research Report By Modality (Neuroimaging, Biopsy, Laboratory Tests, Genetic Testing), By Biomarker (IDH1, ATRX, BRAF, EGFR, MGMT), By Diagnostic Purpose (Pre-Operative Diagnosis, Post-Operative Monitoring, Treatment Selection, Prognosis Prediction), By Imaging Technique (Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT)), By Sample Type (Tissue Biopsy, Blood, Cerebrospinal Fluid (CSF)) and By Region (North America, Europe, South America, Asia Pacific, Middle East and Africa- Growth & Industry Forecast 2025 To 2035

Brain Tumor Diagnostics Market Infographic

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1.1 EXECUTIVE SUMMARY
1.1.1 Market Overview
1.1.2 Key Findings
1.1.3 Market Segmentation
1.1.4 Competitive Landscape
1.1.5 Challenges and Opportunities
1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
2.1 MARKET INTRODUCTION
2.1.1 Definition
2.1.2 Scope of the study
2.1.2.1 Research Objective
2.1.2.2 Assumption
2.1.2.3 Limitations
2.2 RESEARCH METHODOLOGY
2.2.1 Overview
2.2.2 Data Mining
2.2.3 Secondary Research
2.2.4 Primary Research
2.2.4.1 Primary Interviews and Information Gathering Process
2.2.4.2 Breakdown of Primary Respondents
2.2.5 Forecasting Model
2.2.6 Market Size Estimation
2.2.6.1 Bottom-Up Approach
2.2.6.2 Top-Down Approach
2.2.7 Data Triangulation
2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
3.1 MARKET DYNAMICS
3.1.1 Overview
3.1.2 Drivers
3.1.3 Restraints
3.1.4 Opportunities
3.2 MARKET FACTOR ANALYSIS
3.2.1 Value chain Analysis
3.2.2 Porter's Five Forces Analysis
3.2.2.1 Bargaining Power of Suppliers
3.2.2.2 Bargaining Power of Buyers
3.2.2.3 Threat of New Entrants
3.2.2.4 Threat of Substitutes
3.2.2.5 Intensity of Rivalry
3.2.3 COVID-19 Impact Analysis
3.2.3.1 Market Impact Analysis
3.2.3.2 Regional Impact
3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
4.1 Healthcare, BY Modality (USD Billion)
4.1.1 Neuroimaging
4.1.2 Biopsy
4.1.3 Laboratory Tests
4.1.4 Genetic Testing
4.2 Healthcare, BY Biomarker (USD Billion)
4.2.1 IDH1
4.2.2 ATRX
4.2.3 BRAF
4.2.4 EGFR
4.2.5 MGMT
4.3 Healthcare, BY Diagnostic Purpose (USD Billion)
4.3.1 Pre-Operative Diagnosis
4.3.2 Post-Operative Monitoring
4.3.3 Treatment Selection
4.3.4 Prognosis Prediction
4.4 Healthcare, BY Imaging Technique (USD Billion)
4.4.1 Magnetic Resonance Imaging (MRI)
4.4.2 Computed Tomography (CT)
4.4.3 Positron Emission Tomography (PET)
4.4.4 Single Photon Emission Computed Tomography (SPECT)
4.5 Healthcare, BY Sample Type (USD Billion)
4.5.1 Tissue Biopsy
4.5.2 Blood
4.5.3 Cerebrospinal Fluid (CSF)
4.6 Healthcare, BY Region (USD Billion)
4.6.1 North America
4.6.1.1 US
4.6.1.2 Canada
4.6.2 Europe
4.6.2.1 Germany
4.6.2.2 UK
4.6.2.3 France
4.6.2.4 Russia
4.6.2.5 Italy
4.6.2.6 Spain
4.6.2.7 Rest of Europe
4.6.3 APAC
4.6.3.1 China
4.6.3.2 India
4.6.3.3 Japan
4.6.3.4 South Korea
4.6.3.5 Malaysia
4.6.3.6 Thailand
4.6.3.7 Indonesia
4.6.3.8 Rest of APAC
4.6.4 South America
4.6.4.1 Brazil
4.6.4.2 Mexico
4.6.4.3 Argentina
4.6.4.4 Rest of South America
4.6.5 MEA
4.6.5.1 GCC Countries
4.6.5.2 South Africa
4.6.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
5.1 Competitive Landscape
5.1.1 Overview
5.1.2 Competitive Analysis
5.1.3 Market share Analysis
5.1.4 Major Growth Strategy in the Healthcare
5.1.5 Competitive Benchmarking
5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
5.1.7 Key developments and growth strategies
5.1.7.1 New Product Launch/Service Deployment
5.1.7.2 Merger & Acquisitions
5.1.7.3 Joint Ventures
5.1.8 Major Players Financial Matrix
5.1.8.1 Sales and Operating Income
5.1.8.2 Major Players R&D Expenditure. 2023
5.2 Company Profiles
5.2.1 Siemens Healthineers (DE)
5.2.1.1 Financial Overview
5.2.1.2 Products Offered
5.2.1.3 Key Developments
5.2.1.4 SWOT Analysis
5.2.1.5 Key Strategies
5.2.2 GE Healthcare (US)
5.2.2.1 Financial Overview
5.2.2.2 Products Offered
5.2.2.3 Key Developments
5.2.2.4 SWOT Analysis
5.2.2.5 Key Strategies
5.2.3 Philips Healthcare (NL)
5.2.3.1 Financial Overview
5.2.3.2 Products Offered
5.2.3.3 Key Developments
5.2.3.4 SWOT Analysis
5.2.3.5 Key Strategies
5.2.4 Roche Diagnostics (CH)
5.2.4.1 Financial Overview
5.2.4.2 Products Offered
5.2.4.3 Key Developments
5.2.4.4 SWOT Analysis
5.2.4.5 Key Strategies
5.2.5 Abbott Laboratories (US)
5.2.5.1 Financial Overview
5.2.5.2 Products Offered
5.2.5.3 Key Developments
5.2.5.4 SWOT Analysis
5.2.5.5 Key Strategies
5.2.6 Bayer AG (DE)
5.2.6.1 Financial Overview
5.2.6.2 Products Offered
5.2.6.3 Key Developments
5.2.6.4 SWOT Analysis
5.2.6.5 Key Strategies
5.2.7 Fujifilm Holdings Corporation (JP)
5.2.7.1 Financial Overview
5.2.7.2 Products Offered
5.2.7.3 Key Developments
5.2.7.4 SWOT Analysis
5.2.7.5 Key Strategies
5.2.8 Canon Medical Systems (JP)
5.2.8.1 Financial Overview
5.2.8.2 Products Offered
5.2.8.3 Key Developments
5.2.8.4 SWOT Analysis
5.2.8.5 Key Strategies
5.2.9 Hitachi Medical Corporation (JP)
5.2.9.1 Financial Overview
5.2.9.2 Products Offered
5.2.9.3 Key Developments
5.2.9.4 SWOT Analysis
5.2.9.5 Key Strategies
5.3 Appendix
5.3.1 References
5.3.2 Related Reports
6 LIST OF FIGURES
6.1 MARKET SYNOPSIS
6.2 NORTH AMERICA MARKET ANALYSIS
6.3 US MARKET ANALYSIS BY MODALITY
6.4 US MARKET ANALYSIS BY BIOMARKER
6.5 US MARKET ANALYSIS BY DIAGNOSTIC PURPOSE
6.6 US MARKET ANALYSIS BY IMAGING TECHNIQUE
6.7 US MARKET ANALYSIS BY SAMPLE TYPE
6.8 CANADA MARKET ANALYSIS BY MODALITY
6.9 CANADA MARKET ANALYSIS BY BIOMARKER
6.10 CANADA MARKET ANALYSIS BY DIAGNOSTIC PURPOSE
6.11 CANADA MARKET ANALYSIS BY IMAGING TECHNIQUE
6.12 CANADA MARKET ANALYSIS BY SAMPLE TYPE
6.13 EUROPE MARKET ANALYSIS
6.14 GERMANY MARKET ANALYSIS BY MODALITY
6.15 GERMANY MARKET ANALYSIS BY BIOMARKER
6.16 GERMANY MARKET ANALYSIS BY DIAGNOSTIC PURPOSE
6.17 GERMANY MARKET ANALYSIS BY IMAGING TECHNIQUE
6.18 GERMANY MARKET ANALYSIS BY SAMPLE TYPE
6.19 UK MARKET ANALYSIS BY MODALITY
6.20 UK MARKET ANALYSIS BY BIOMARKER
6.21 UK MARKET ANALYSIS BY DIAGNOSTIC PURPOSE
6.22 UK MARKET ANALYSIS BY IMAGING TECHNIQUE
6.23 UK MARKET ANALYSIS BY SAMPLE TYPE
6.24 FRANCE MARKET ANALYSIS BY MODALITY
6.25 FRANCE MARKET ANALYSIS BY BIOMARKER
6.26 FRANCE MARKET ANALYSIS BY DIAGNOSTIC PURPOSE
6.27 FRANCE MARKET ANALYSIS BY IMAGING TECHNIQUE
6.28 FRANCE MARKET ANALYSIS BY SAMPLE TYPE
6.29 RUSSIA MARKET ANALYSIS BY MODALITY
6.30 RUSSIA MARKET ANALYSIS BY BIOMARKER
6.31 RUSSIA MARKET ANALYSIS BY DIAGNOSTIC PURPOSE
6.32 RUSSIA MARKET ANALYSIS BY IMAGING TECHNIQUE
6.33 RUSSIA MARKET ANALYSIS BY SAMPLE TYPE
6.34 ITALY MARKET ANALYSIS BY MODALITY
6.35 ITALY MARKET ANALYSIS BY BIOMARKER
6.36 ITALY MARKET ANALYSIS BY DIAGNOSTIC PURPOSE
6.37 ITALY MARKET ANALYSIS BY IMAGING TECHNIQUE
6.38 ITALY MARKET ANALYSIS BY SAMPLE TYPE
6.39 SPAIN MARKET ANALYSIS BY MODALITY
6.40 SPAIN MARKET ANALYSIS BY BIOMARKER
6.41 SPAIN MARKET ANALYSIS BY DIAGNOSTIC PURPOSE
6.42 SPAIN MARKET ANALYSIS BY IMAGING TECHNIQUE
6.43 SPAIN MARKET ANALYSIS BY SAMPLE TYPE
6.44 REST OF EUROPE MARKET ANALYSIS BY MODALITY
6.45 REST OF EUROPE MARKET ANALYSIS BY BIOMARKER
6.46 REST OF EUROPE MARKET ANALYSIS BY DIAGNOSTIC PURPOSE
6.47 REST OF EUROPE MARKET ANALYSIS BY IMAGING TECHNIQUE
6.48 REST OF EUROPE MARKET ANALYSIS BY SAMPLE TYPE
6.49 APAC MARKET ANALYSIS
6.50 CHINA MARKET ANALYSIS BY MODALITY
6.51 CHINA MARKET ANALYSIS BY BIOMARKER
6.52 CHINA MARKET ANALYSIS BY DIAGNOSTIC PURPOSE
6.53 CHINA MARKET ANALYSIS BY IMAGING TECHNIQUE
6.54 CHINA MARKET ANALYSIS BY SAMPLE TYPE
6.55 INDIA MARKET ANALYSIS BY MODALITY
6.56 INDIA MARKET ANALYSIS BY BIOMARKER
6.57 INDIA MARKET ANALYSIS BY DIAGNOSTIC PURPOSE
6.58 INDIA MARKET ANALYSIS BY IMAGING TECHNIQUE
6.59 INDIA MARKET ANALYSIS BY SAMPLE TYPE
6.60 JAPAN MARKET ANALYSIS BY MODALITY
6.61 JAPAN MARKET ANALYSIS BY BIOMARKER
6.62 JAPAN MARKET ANALYSIS BY DIAGNOSTIC PURPOSE
6.63 JAPAN MARKET ANALYSIS BY IMAGING TECHNIQUE
6.64 JAPAN MARKET ANALYSIS BY SAMPLE TYPE
6.65 SOUTH KOREA MARKET ANALYSIS BY MODALITY
6.66 SOUTH KOREA MARKET ANALYSIS BY BIOMARKER
6.67 SOUTH KOREA MARKET ANALYSIS BY DIAGNOSTIC PURPOSE
6.68 SOUTH KOREA MARKET ANALYSIS BY IMAGING TECHNIQUE
6.69 SOUTH KOREA MARKET ANALYSIS BY SAMPLE TYPE
6.70 MALAYSIA MARKET ANALYSIS BY MODALITY
6.71 MALAYSIA MARKET ANALYSIS BY BIOMARKER
6.72 MALAYSIA MARKET ANALYSIS BY DIAGNOSTIC PURPOSE
6.73 MALAYSIA MARKET ANALYSIS BY IMAGING TECHNIQUE
6.74 MALAYSIA MARKET ANALYSIS BY SAMPLE TYPE
6.75 THAILAND MARKET ANALYSIS BY MODALITY
6.76 THAILAND MARKET ANALYSIS BY BIOMARKER
6.77 THAILAND MARKET ANALYSIS BY DIAGNOSTIC PURPOSE
6.78 THAILAND MARKET ANALYSIS BY IMAGING TECHNIQUE
6.79 THAILAND MARKET ANALYSIS BY SAMPLE TYPE
6.80 INDONESIA MARKET ANALYSIS BY MODALITY
6.81 INDONESIA MARKET ANALYSIS BY BIOMARKER
6.82 INDONESIA MARKET ANALYSIS BY DIAGNOSTIC PURPOSE
6.83 INDONESIA MARKET ANALYSIS BY IMAGING TECHNIQUE
6.84 INDONESIA MARKET ANALYSIS BY SAMPLE TYPE
6.85 REST OF APAC MARKET ANALYSIS BY MODALITY
6.86 REST OF APAC MARKET ANALYSIS BY BIOMARKER
6.87 REST OF APAC MARKET ANALYSIS BY DIAGNOSTIC PURPOSE
6.88 REST OF APAC MARKET ANALYSIS BY IMAGING TECHNIQUE
6.89 REST OF APAC MARKET ANALYSIS BY SAMPLE TYPE
6.90 SOUTH AMERICA MARKET ANALYSIS
6.91 BRAZIL MARKET ANALYSIS BY MODALITY
6.92 BRAZIL MARKET ANALYSIS BY BIOMARKER
6.93 BRAZIL MARKET ANALYSIS BY DIAGNOSTIC PURPOSE
6.94 BRAZIL MARKET ANALYSIS BY IMAGING TECHNIQUE
6.95 BRAZIL MARKET ANALYSIS BY SAMPLE TYPE
6.96 MEXICO MARKET ANALYSIS BY MODALITY
6.97 MEXICO MARKET ANALYSIS BY BIOMARKER
6.98 MEXICO MARKET ANALYSIS BY DIAGNOSTIC PURPOSE
6.99 MEXICO MARKET ANALYSIS BY IMAGING TECHNIQUE
6.100 MEXICO MARKET ANALYSIS BY SAMPLE TYPE
6.101 ARGENTINA MARKET ANALYSIS BY MODALITY
6.102 ARGENTINA MARKET ANALYSIS BY BIOMARKER
6.103 ARGENTINA MARKET ANALYSIS BY DIAGNOSTIC PURPOSE
6.104 ARGENTINA MARKET ANALYSIS BY IMAGING TECHNIQUE
6.105 ARGENTINA MARKET ANALYSIS BY SAMPLE TYPE
6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY MODALITY
6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY BIOMARKER
6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY DIAGNOSTIC PURPOSE
6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY IMAGING TECHNIQUE
6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY SAMPLE TYPE
6.111 MEA MARKET ANALYSIS
6.112 GCC COUNTRIES MARKET ANALYSIS BY MODALITY
6.113 GCC COUNTRIES MARKET ANALYSIS BY BIOMARKER
6.114 GCC COUNTRIES MARKET ANALYSIS BY DIAGNOSTIC PURPOSE
6.115 GCC COUNTRIES MARKET ANALYSIS BY IMAGING TECHNIQUE
6.116 GCC COUNTRIES MARKET ANALYSIS BY SAMPLE TYPE
6.117 SOUTH AFRICA MARKET ANALYSIS BY MODALITY
6.118 SOUTH AFRICA MARKET ANALYSIS BY BIOMARKER
6.119 SOUTH AFRICA MARKET ANALYSIS BY DIAGNOSTIC PURPOSE
6.120 SOUTH AFRICA MARKET ANALYSIS BY IMAGING TECHNIQUE
6.121 SOUTH AFRICA MARKET ANALYSIS BY SAMPLE TYPE
6.122 REST OF MEA MARKET ANALYSIS BY MODALITY
6.123 REST OF MEA MARKET ANALYSIS BY BIOMARKER
6.124 REST OF MEA MARKET ANALYSIS BY DIAGNOSTIC PURPOSE
6.125 REST OF MEA MARKET ANALYSIS BY IMAGING TECHNIQUE
6.126 REST OF MEA MARKET ANALYSIS BY SAMPLE TYPE
6.127 KEY BUYING CRITERIA OF HEALTHCARE
6.128 RESEARCH PROCESS OF MRFR
6.129 DRO ANALYSIS OF HEALTHCARE
6.130 DRIVERS IMPACT ANALYSIS: HEALTHCARE
6.131 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
6.132 SUPPLY / VALUE CHAIN: HEALTHCARE
6.133 HEALTHCARE, BY MODALITY, 2024 (% SHARE)
6.134 HEALTHCARE, BY MODALITY, 2024 TO 2035 (USD Billion)
6.135 HEALTHCARE, BY BIOMARKER, 2024 (% SHARE)
6.136 HEALTHCARE, BY BIOMARKER, 2024 TO 2035 (USD Billion)
6.137 HEALTHCARE, BY DIAGNOSTIC PURPOSE, 2024 (% SHARE)
6.138 HEALTHCARE, BY DIAGNOSTIC PURPOSE, 2024 TO 2035 (USD Billion)
6.139 HEALTHCARE, BY IMAGING TECHNIQUE, 2024 (% SHARE)
6.140 HEALTHCARE, BY IMAGING TECHNIQUE, 2024 TO 2035 (USD Billion)
6.141 HEALTHCARE, BY SAMPLE TYPE, 2024 (% SHARE)
6.142 HEALTHCARE, BY SAMPLE TYPE, 2024 TO 2035 (USD Billion)
6.143 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
7.1 LIST OF ASSUMPTIONS
7.1.1
7.2 North America MARKET SIZE ESTIMATES; FORECAST
7.2.1 BY MODALITY, 2025-2035 (USD Billion)
7.2.2 BY BIOMARKER, 2025-2035 (USD Billion)
7.2.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
7.2.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
7.2.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
7.3 US MARKET SIZE ESTIMATES; FORECAST
7.3.1 BY MODALITY, 2025-2035 (USD Billion)
7.3.2 BY BIOMARKER, 2025-2035 (USD Billion)
7.3.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
7.3.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
7.3.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
7.4 Canada MARKET SIZE ESTIMATES; FORECAST
7.4.1 BY MODALITY, 2025-2035 (USD Billion)
7.4.2 BY BIOMARKER, 2025-2035 (USD Billion)
7.4.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
7.4.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
7.4.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
7.5 Europe MARKET SIZE ESTIMATES; FORECAST
7.5.1 BY MODALITY, 2025-2035 (USD Billion)
7.5.2 BY BIOMARKER, 2025-2035 (USD Billion)
7.5.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
7.5.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
7.5.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
7.6 Germany MARKET SIZE ESTIMATES; FORECAST
7.6.1 BY MODALITY, 2025-2035 (USD Billion)
7.6.2 BY BIOMARKER, 2025-2035 (USD Billion)
7.6.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
7.6.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
7.6.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
7.7 UK MARKET SIZE ESTIMATES; FORECAST
7.7.1 BY MODALITY, 2025-2035 (USD Billion)
7.7.2 BY BIOMARKER, 2025-2035 (USD Billion)
7.7.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
7.7.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
7.7.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
7.8 France MARKET SIZE ESTIMATES; FORECAST
7.8.1 BY MODALITY, 2025-2035 (USD Billion)
7.8.2 BY BIOMARKER, 2025-2035 (USD Billion)
7.8.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
7.8.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
7.8.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
7.9 Russia MARKET SIZE ESTIMATES; FORECAST
7.9.1 BY MODALITY, 2025-2035 (USD Billion)
7.9.2 BY BIOMARKER, 2025-2035 (USD Billion)
7.9.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
7.9.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
7.9.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
7.10 Italy MARKET SIZE ESTIMATES; FORECAST
7.10.1 BY MODALITY, 2025-2035 (USD Billion)
7.10.2 BY BIOMARKER, 2025-2035 (USD Billion)
7.10.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
7.10.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
7.10.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
7.11 Spain MARKET SIZE ESTIMATES; FORECAST
7.11.1 BY MODALITY, 2025-2035 (USD Billion)
7.11.2 BY BIOMARKER, 2025-2035 (USD Billion)
7.11.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
7.11.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
7.11.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
7.12.1 BY MODALITY, 2025-2035 (USD Billion)
7.12.2 BY BIOMARKER, 2025-2035 (USD Billion)
7.12.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
7.12.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
7.12.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
7.13 APAC MARKET SIZE ESTIMATES; FORECAST
7.13.1 BY MODALITY, 2025-2035 (USD Billion)
7.13.2 BY BIOMARKER, 2025-2035 (USD Billion)
7.13.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
7.13.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
7.13.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
7.14 China MARKET SIZE ESTIMATES; FORECAST
7.14.1 BY MODALITY, 2025-2035 (USD Billion)
7.14.2 BY BIOMARKER, 2025-2035 (USD Billion)
7.14.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
7.14.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
7.14.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
7.15 India MARKET SIZE ESTIMATES; FORECAST
7.15.1 BY MODALITY, 2025-2035 (USD Billion)
7.15.2 BY BIOMARKER, 2025-2035 (USD Billion)
7.15.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
7.15.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
7.15.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
7.16 Japan MARKET SIZE ESTIMATES; FORECAST
7.16.1 BY MODALITY, 2025-2035 (USD Billion)
7.16.2 BY BIOMARKER, 2025-2035 (USD Billion)
7.16.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
7.16.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
7.16.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
7.17.1 BY MODALITY, 2025-2035 (USD Billion)
7.17.2 BY BIOMARKER, 2025-2035 (USD Billion)
7.17.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
7.17.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
7.17.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
7.18.1 BY MODALITY, 2025-2035 (USD Billion)
7.18.2 BY BIOMARKER, 2025-2035 (USD Billion)
7.18.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
7.18.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
7.18.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
7.19.1 BY MODALITY, 2025-2035 (USD Billion)
7.19.2 BY BIOMARKER, 2025-2035 (USD Billion)
7.19.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
7.19.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
7.19.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
7.20.1 BY MODALITY, 2025-2035 (USD Billion)
7.20.2 BY BIOMARKER, 2025-2035 (USD Billion)
7.20.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
7.20.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
7.20.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
7.21.1 BY MODALITY, 2025-2035 (USD Billion)
7.21.2 BY BIOMARKER, 2025-2035 (USD Billion)
7.21.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
7.21.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
7.21.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
7.22 South America MARKET SIZE ESTIMATES; FORECAST
7.22.1 BY MODALITY, 2025-2035 (USD Billion)
7.22.2 BY BIOMARKER, 2025-2035 (USD Billion)
7.22.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
7.22.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
7.22.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
7.23.1 BY MODALITY, 2025-2035 (USD Billion)
7.23.2 BY BIOMARKER, 2025-2035 (USD Billion)
7.23.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
7.23.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
7.23.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
7.24.1 BY MODALITY, 2025-2035 (USD Billion)
7.24.2 BY BIOMARKER, 2025-2035 (USD Billion)
7.24.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
7.24.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
7.24.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
7.25.1 BY MODALITY, 2025-2035 (USD Billion)
7.25.2 BY BIOMARKER, 2025-2035 (USD Billion)
7.25.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
7.25.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
7.25.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
7.26.1 BY MODALITY, 2025-2035 (USD Billion)
7.26.2 BY BIOMARKER, 2025-2035 (USD Billion)
7.26.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
7.26.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
7.26.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
7.27 MEA MARKET SIZE ESTIMATES; FORECAST
7.27.1 BY MODALITY, 2025-2035 (USD Billion)
7.27.2 BY BIOMARKER, 2025-2035 (USD Billion)
7.27.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
7.27.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
7.27.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
7.28.1 BY MODALITY, 2025-2035 (USD Billion)
7.28.2 BY BIOMARKER, 2025-2035 (USD Billion)
7.28.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
7.28.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
7.28.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
7.29.1 BY MODALITY, 2025-2035 (USD Billion)
7.29.2 BY BIOMARKER, 2025-2035 (USD Billion)
7.29.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
7.29.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
7.29.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
7.30.1 BY MODALITY, 2025-2035 (USD Billion)
7.30.2 BY BIOMARKER, 2025-2035 (USD Billion)
7.30.3 BY DIAGNOSTIC PURPOSE, 2025-2035 (USD Billion)
7.30.4 BY IMAGING TECHNIQUE, 2025-2035 (USD Billion)
7.30.5 BY SAMPLE TYPE, 2025-2035 (USD Billion)
7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Healthcare Market Segmentation

Healthcare By Modality (USD Billion, 2025-2035)

Neuroimaging
Biopsy
Laboratory Tests
Genetic Testing

Healthcare By Biomarker (USD Billion, 2025-2035)

IDH1
ATRX
BRAF
EGFR
MGMT

Healthcare By Diagnostic Purpose (USD Billion, 2025-2035)

Pre-Operative Diagnosis
Post-Operative Monitoring
Treatment Selection
Prognosis Prediction

Healthcare By Imaging Technique (USD Billion, 2025-2035)

Magnetic Resonance Imaging (MRI)
Computed Tomography (CT)
Positron Emission Tomography (PET)
Single Photon Emission Computed Tomography (SPECT)

Healthcare By Sample Type (USD Billion, 2025-2035)

Tissue Biopsy
Blood
Cerebrospinal Fluid (CSF)

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Features	License Type
Features	Single User	Multiuser License	Enterprise User
Price	$4,950	$5,950	$7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout the Organization
Free Customization	✓	✓	✓
Direct Access to Analyst	✓	✓	✓
Deliverable Format	✓	✓	✓
Platform Access	✗	✗	✓
Discount on Next Purchase	10%	15%	15%
Printable Versions	✗	✗	✓